253 related articles for article (PubMed ID: 26352111)
21. Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays.
Moreau C; Autier B; Cavey T; Rouger E; Norwood J; Bendavid C; Escoffre M; Sébillot M; Decaux O
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):693-704. PubMed ID: 27618362
[TBL] [Abstract][Full Text] [Related]
22. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
23. Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal Insufficiency.
Xu L; Zhao B; Sun Y; Wang S; Chen X; Mao Y
Biomed Res Int; 2022; 2022():5536199. PubMed ID: 35392256
[TBL] [Abstract][Full Text] [Related]
24. Serum free light chain analysis: persisting limitations with new kids on the block.
Van Hoovels L; Vercammen M; Nevejan L; Cornette M; Briers PJ; Deeren D; Van Droogenbroeck J; Fostier K; De Smet D
Clin Chem Lab Med; 2022 Aug; 60(9):1440-1448. PubMed ID: 35781357
[TBL] [Abstract][Full Text] [Related]
25. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
26. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
Shaheen SP; Levinson SS
Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
[TBL] [Abstract][Full Text] [Related]
27. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
29. Performance Evaluation of Serum Free Light Chain Analysis: Nephelometry vs Turbidimetry, Monoclonal vs Polyclonal Reagents.
Messiaen AS; De Sloovere MMW; Claus PE; Vercammen M; Van Hoovels L; Heylen O; Debrabandere J; Vanpoucke H; De Smet D
Am J Clin Pathol; 2017 Jun; 147(6):611-622. PubMed ID: 28575180
[TBL] [Abstract][Full Text] [Related]
30. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
31. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
Wood PB; McElroy YG; Stone MJ
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
[TBL] [Abstract][Full Text] [Related]
32. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
Zhu GQ; Fu X; Ren YS; Wang YS; Wang SL; Wang LC; Lin J; An G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1209-1215. PubMed ID: 34362504
[TBL] [Abstract][Full Text] [Related]
33. [Detection of free light chains--a new method of diagnostics of haematological diseases].
Mecl J; Benáková H; Nohejlová A; Straub J; Zima T; Spicka I
Cas Lek Cesk; 2007; 146(2):159-62. PubMed ID: 17373113
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods.
Jacobs JFM; de Kat Angelino CM; Brouwers HMLM; Croockewit SA; Joosten I; van der Molen RG
Clin Chem Lab Med; 2018 Jan; 56(2):312-322. PubMed ID: 28771430
[TBL] [Abstract][Full Text] [Related]
35. Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains.
Farnsworth CW; Roemmich B; Spears GM; Murray DL; Dispenzieri A; Willrich MAV
Clin Chem Lab Med; 2024 Apr; 62(5):929-938. PubMed ID: 38044587
[TBL] [Abstract][Full Text] [Related]
36. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
[TBL] [Abstract][Full Text] [Related]
37. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents.
Carr-Smith HD; Jenner EL; Evans JA; Harding SJ
Clin Chem Lab Med; 2016 Jun; 54(6):997-1003. PubMed ID: 26943608
[TBL] [Abstract][Full Text] [Related]
38. N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda.
Velthuis HT; Knop I; Stam P; van den Broek M; Bos HK; Hol S; Teunissen E; Fischedick KS; Althaus H; Schmidt B; Wagner C; Melsert R
Clin Chem Lab Med; 2011 Aug; 49(8):1323-1332. PubMed ID: 21663464
[TBL] [Abstract][Full Text] [Related]
39. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
40. A multicentre study comparing two methods for serum free light chain analysis.
Lock RJ; Saleem R; Roberts EG; Wallage MJ; Pesce TJ; Rowbottom A; Cooper SJ; McEvoy ED; Taylor JL; Basu S
Ann Clin Biochem; 2013 May; 50(Pt 3):255-61. PubMed ID: 23605135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
